DE69330745D1 - Chemerische immunogene - Google Patents

Chemerische immunogene

Info

Publication number
DE69330745D1
DE69330745D1 DE69330745T DE69330745T DE69330745D1 DE 69330745 D1 DE69330745 D1 DE 69330745D1 DE 69330745 T DE69330745 T DE 69330745T DE 69330745 T DE69330745 T DE 69330745T DE 69330745 D1 DE69330745 D1 DE 69330745D1
Authority
DE
Germany
Prior art keywords
protein
piv
rsv
gene sequence
pathogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69330745T
Other languages
English (en)
Other versions
DE69330745T2 (de
Inventor
H Klein
Run-Pan Du
E Ewasyshyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Aventis Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur Ltd filed Critical Aventis Pasteur Ltd
Application granted granted Critical
Publication of DE69330745D1 publication Critical patent/DE69330745D1/de
Publication of DE69330745T2 publication Critical patent/DE69330745T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/135—Respiratory syncytial virus
DE69330745T 1992-01-06 1993-01-05 Chemerische immunogene Expired - Lifetime DE69330745T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929200117A GB9200117D0 (en) 1992-01-06 1992-01-06 Production of recombinant chimeric proteins for vaccine use
PCT/CA1993/000001 WO1993014207A1 (en) 1992-01-06 1993-01-05 Chimeric immunogens

Publications (2)

Publication Number Publication Date
DE69330745D1 true DE69330745D1 (de) 2001-10-18
DE69330745T2 DE69330745T2 (de) 2002-05-29

Family

ID=10708117

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330745T Expired - Lifetime DE69330745T2 (de) 1992-01-06 1993-01-05 Chemerische immunogene

Country Status (16)

Country Link
US (13) US6225091B1 (de)
EP (1) EP0621898B1 (de)
JP (1) JP3290662B2 (de)
KR (1) KR100208310B1 (de)
AT (1) ATE205535T1 (de)
AU (1) AU667502B2 (de)
CA (1) CA2126863C (de)
DE (1) DE69330745T2 (de)
DK (1) DK0621898T3 (de)
ES (1) ES2164070T3 (de)
FI (1) FI117514B (de)
GB (1) GB9200117D0 (de)
NO (1) NO316622B1 (de)
PT (1) PT621898E (de)
RU (1) RU2123047C1 (de)
WO (1) WO1993014207A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
FR2726472B1 (fr) 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US5993824A (en) 1996-07-15 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
FR2751229B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7314631B1 (en) 1997-05-23 2008-01-01 The United States Of America As Represented By The Department Of Health And Human Services Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
WO2000018929A2 (en) * 1998-09-25 2000-04-06 Smithkline Beecham Biologicals S.A. Paramyxovirus vaccines
MXPA02000220A (es) 1999-07-09 2005-08-16 Gov Health & Human Serv Produccion de vacunas quimericas humanas-bovinas atenuadas del virus sincitial respiratorio.
CA2378661A1 (en) * 1999-07-09 2001-01-18 Alexander C. Schmidt Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
EP1351981B1 (de) 2001-01-19 2012-08-08 Vironovative B.V. Ein erkrankungen der atemwege verursachendes virus in säugern
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
JP4553589B2 (ja) 2002-02-21 2010-09-29 メディミューン，エルエルシー 組換えパラインフルエンザウイルス発現系とメタニューモウイルスから得られる異種抗原を含むワクチン
CN1665932B (zh) * 2002-04-30 2010-12-15 株式会社载体研究所 具有修饰的蛋白酶依赖向性的载体
WO2004010935A2 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
US20060110740A1 (en) * 2003-01-20 2006-05-25 Julia Hurwitz Use of sendai virus as a human parainfluenza vaccine
ATE469170T1 (de) * 2003-03-28 2010-06-15 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
EP2494987A1 (de) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirusstämme und deren Verwendung in Impfstoffformulierungen und als Vektoren für die Expression antigener Sequenzen und Verfahren zur Ausbreitung des Virus
CA2594612A1 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
EP2476432B1 (de) 2006-03-07 2015-08-19 Vaxinnate Corporation Zusammensetzungen mit Hämagglutinin, Verfahren zu ihrer Herstellung und Verfahren zu ihrer Verwendung
DE102006060799A1 (de) 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
ES2566156T3 (es) 2009-02-02 2016-04-11 Chrontech Pharma Ab Antígeno del núcleo del virus de la hepatitis B (HBcAg) con codones optimizados
KR20120093811A (ko) * 2009-06-24 2012-08-23 아이디 바이오메디컬 코포레이션 오브 퀘벡 백신
CA2825722A1 (en) * 2011-01-28 2012-08-02 Medimmune, Llc Expression of soluble viral fusion glycoproteins in mammalian cells
WO2013031827A1 (ja) 2011-08-29 2013-03-07 国立大学法人徳島大学 Rsv粘膜ワクチン
US9662379B2 (en) 2011-12-02 2017-05-30 Rhode Island Hospital Vaccine for falciparum malaria
MX362511B (es) 2012-08-01 2019-01-22 Bavarian Nordic As Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr).
US20160324954A1 (en) 2013-05-15 2016-11-10 Chrontech Pharma Ab Immunogenic compositions for inhibiting hepatitis d virus
SI3718565T1 (sl) 2015-10-22 2022-08-31 Modernatx, Inc. Cepiva za respiratorni virus
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
US20200030432A1 (en) 2017-03-17 2020-01-30 Modernatx, Inc. Zoonotic disease rna vaccines
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
EP0175261B1 (de) * 1984-09-12 1991-12-11 Chiron Corporation Hybridpartikel-Immunogene
US4722898A (en) * 1985-04-29 1988-02-02 Minnesota Mining And Manufacturing Company Immobilization of biological cells in polytetrafluoroethylene matrix
GB8610983D0 (en) * 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5098998A (en) * 1987-04-29 1992-03-24 President And Fellows Of Harvard College Cholera vaccines and peptides
ES2054769T3 (es) * 1987-11-16 1994-08-16 Hoffmann La Roche Polipeptidos hiv-2 recombinantes.
DE3878468T2 (de) * 1987-12-23 1993-06-09 Upjohn Co Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
EP0413695B1 (de) * 1988-04-22 1994-05-04 The Upjohn Company Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3
FR2636842B1 (fr) 1988-09-27 1994-06-10 Liege Universite Etat Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion
CA2025481A1 (en) 1989-09-19 1991-03-20 Peter J. Kniskern Vaccine for aids and hepatitis b
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus

Also Published As

Publication number Publication date
KR100208310B1 (ko) 1999-07-15
NO942530L (no) 1994-09-05
US20080015340A1 (en) 2008-01-17
AU667502B2 (en) 1996-03-28
CA2126863A1 (en) 1993-07-22
ES2164070T3 (es) 2002-02-16
FI943211A0 (fi) 1994-07-05
CA2126863C (en) 1999-08-10
US7244589B2 (en) 2007-07-17
US7514535B2 (en) 2009-04-07
AU3340293A (en) 1993-08-03
EP0621898B1 (de) 2001-09-12
US7405273B2 (en) 2008-07-29
JPH07501707A (ja) 1995-02-23
DE69330745T2 (de) 2002-05-29
US20080027213A1 (en) 2008-01-31
US20080032342A1 (en) 2008-02-07
US20080311624A1 (en) 2008-12-18
US20050136067A1 (en) 2005-06-23
RU2123047C1 (ru) 1998-12-10
EP0621898A1 (de) 1994-11-02
US7498153B2 (en) 2009-03-03
DK0621898T3 (da) 2001-11-12
US6168786B1 (en) 2001-01-02
FI943211A (fi) 1994-09-02
PT621898E (pt) 2002-03-28
US7671186B2 (en) 2010-03-02
US6017539A (en) 2000-01-25
US6171783B1 (en) 2001-01-09
FI117514B (fi) 2006-11-15
US20080312412A1 (en) 2008-12-18
US7619063B2 (en) 2009-11-17
US5968776A (en) 1999-10-19
RU94042722A (ru) 1996-09-10
US6033668A (en) 2000-03-07
JP3290662B2 (ja) 2002-06-10
US6225091B1 (en) 2001-05-01
US5998169A (en) 1999-12-07
GB9200117D0 (en) 1992-02-26
ATE205535T1 (de) 2001-09-15
NO316622B1 (no) 2004-03-15
WO1993014207A1 (en) 1993-07-22
NO942530D0 (no) 1994-07-05

Similar Documents

Publication Publication Date Title
DE69330745D1 (de) Chemerische immunogene
Weck et al. Antiviral activities of hybrids of two major human leukocyte interferons
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
DK0770679T3 (da) HCV-specifikke peptider, præparater indeholdende dem og anvendelse deraf
WO1992017493A3 (en) Peptides and mixtures thereof for detecting antibodies to hepatitis c virus (hcv)
DK0853487T3 (da) Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
DE69428214T2 (de) Transformierender wachstumsfaktor alpha h1
DE3878468T2 (de) Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
DK251890A (da) Polypeptid og dets anvendelse samt ekspressionssystem til dets eksprimering
ATE263243T1 (de) Schützende antikörper induzierende antigene aus plasmodium falciparum
DE69515613T2 (de) Immunogenes Hybridprotein OprF-Oprl erhältlich aus Membranproteinen von Pseudomonas aeruginosa
BR9202024A (pt) Virus de apivox recombinante,cultura de celulas eucariotica infectadas por um virus de avipox,vacina,sequencia de transferencia e plasmideo
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
Dietzschold et al. Serological characterization of the three major proteins of vesicular stomatitis virus
DK482788D0 (da) Vacciner mod og diagnostiske bestemmelser af haemophilus influenzae
ATE342920T1 (de) Methylierte smd homologe peptide, die mit antikörpern aus sera von lebewesen mit systemischer lupus erythematodes reagieren
LU et al. Preparation and development of equine hyperimmune globulin F (ab′) 2 against severe acute respiratory syndrome coronavirus 1
EP0432220A4 (en) Vaccines and diagnostic assays for haemophilus influenzae
WO2004005316A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
DE69334276D1 (de) Immunreaktive peptide des epstein-barrvirus
HU9201590D0 (en) Recombinant vaccine against marek's illness
JPH03135923A (ja) 百日咳毒素ｂオリゴマーの構成サブユニットを含有する経鼻接種ワクチン
ATE459708T1 (de) Herstellung von infektiöser respiratorischer synzitial virus aus klonierten nukleotid sequenzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 621898

Country of ref document: EP